Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $90

Benzinga Newsdesk www.benzinga.com Neutral 74.9%

Neg 0% Neu 74.9% Pos 0%

Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $100 to $90.